Table 1.
Clinical characteristics: patients with T2DM attending the Hillbrow Community Health Centre.
| Characteristic | Number of patients and % of those tested with variable |
|---|---|
| Age (years) | 53.9 ± 11.5 |
| Female sex, n (%) | 280 (53.9) |
| Ethnicity: Black African, n (%)/other, n (%) | 515 (99.2)/4 (0.8) |
| Cardiovascular disease, n (%) | 2 (0.4) |
| Stroke/TIA, n (%) | 1 (0.2) |
| Retinopathy, n (%) | 4 (0.8) |
| Neuropathy, n (%) | 3 (0.6) |
| Nephropathy, n (%) | 1 (0.2) |
| HbA1c (%) | 9.1 ± 2.6 |
| Systolic BP (mmHg) | 138 ± 18.4 |
| Diastolic BP (mmHg) | 82 ± 10.3 |
| TC (mmol/L) | 4.2 ± 1 |
| TG (mmol/L) | 1.5 ± 0.9 |
| LDL-C (mmol/L) | 2.4 ± 0.9 |
| HDL-C (mmol/L) | 1.1 ± 0.3 |
| Glycaemic control agents | |
| Diet only, n (%) | 9 (1.7) |
| 1 oral, no insulin, n (%) | 115 (22.2) |
| ≥2 oral, no insulin, n (%) | 140 (27.0) |
| Insulin only, n (%) | 47 (9.1) |
| Combination—insulin with 1 oral, n (%) | 202 (38.9) |
| Combination—insulin with ≥2 oral, n (%) | 6 (1.2) |
| Biguanides, n (%) | 450 (86.7) |
| Sulphonylureas, n (%) | 159 (30.6) |
| Antihypertensive agents | |
| Antihypertensive treatment, n (%) | 459 (88.4) |
| Monotherapy, n (%) | 115 (25.1) |
| Combination therapy (2 classes), n (%) | 121 (26.4) |
| Combination therapy (3 classes), n (%) | 132 (28.8) |
| Combination therapy (4 classes), n (%) | 67 (14.6) |
| Combination therapy (≥5 classes), n (%) | 24 (5.2) |
| ACE inhibitors, n (%) | 403 (87.8) |
| Lipid-lowering agents | |
| Statin treatment, n (%) | 133 (25.6) |
| Other agents | |
| Antiplatelet treatment, n (%) | 136 (26.2) |
| Thyroid treatment, n (%) | 6 (1.2) |
BP: blood pressure; HbA1c: glycated haemoglobin; HDL: high-density lipoprotein; LDL: low-density lipoprotein; TC: total cholesterol; TG: triglyceride; TIA: transient ischaemic attack.